Authors : Chiu Lan Hsieh , Chiung-Huei Peng , George T. Hsiao , Hui Er Wang , Wan-Shen Ko and Robert Y. Peng
Abstract: Hepatocellular Cancer Cell (HCC) lines HepG2, HA22T and KEL FIB were used to test the therapeutic effect of different combined protocols for etodolac plus 5-FU: 1). the selective COX 2 inhibitor etodolac alone at 0.0~0.16 �g �L 1; 2). 5-FU alone at 0.0~1.25 �g mL 1; 3). etodolac (0.31 �g �L 1) plus 5-FU (1.25 �g mL 1) in a simultaneous-, or an alternative sequential protocol. Cell viability was measured using MTT assay and flow cytometric analysis. An inverse dose dependent survival rate was observed for both drugs, while the apoptotic data of the three HCC cell lines have favored the simultaneous administration of etodolac plus 5-FU, which revealed to be more effective than administering etodolac or 5-FU alone. We conclude that in view of the therapeutic efficacy with a minimized cytotoxicity, a simultaneous administration of etodolac plus 5-FU, each at much more reduced dosages than usually prescribed alone, could be strongly recommended for treatment of HCC.
Chiu Lan Hsieh , Chiung-Huei Peng , George T. Hsiao , Hui Er Wang , Wan-Shen Ko and Robert Y. Peng , 2007. Synergistic Effect of Combined Etodolac Plus 5-Fluorouracil in Human Hepatoma Therapy--an In vitro Evaluation by Cell Lines HepG2, HA22T and KELFIB. Research Journal of Biological Sciences, 2: 268-279.